cours de bourse
14/08/2009 - 11:07:23|49.66 EUR 0.42 %
Strong sales growth in Q1 2015 (up 7.5%) exceeding targets
Positive performance in all geographic regions
Significant growth in the...
STG320 is the first house dust mite immunotherapy tablet ever to obtain a...
Stallergenes is a global pharmaceutical company with leading innovation, provider of allergy solutions all around the world.
Stallergenes’ comprehensive approach to allergic diseases includes a complete portfolio combining diagnosis products and treatments and a new generation of allergen immunotherapy treatments.